These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26935370)

  • 1. A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone.
    Sato S; Hanibuchi M; Takahashi M; Fukuda Y; Morizumi S; Toyoda Y; Goto H; Nishioka Y
    Intern Med; 2016; 55(5):497-501. PubMed ID: 26935370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal.
    Watanabe K; Ishii H; Kiyomi F; Terasaki Y; Hebisawa A; Kawabata Y; Johkoh T; Sakai F; Kondoh Y; Inoue Y; Azuma A; Suda T; Ogura T; Inase N; Homma S;
    Respir Investig; 2019 Jul; 57(4):312-320. PubMed ID: 30981683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report.
    Hurtado EJ; González ML; Soto Mdel M; Rueda FJ; Nadal FJ; Cantero AR
    Chron Respir Dis; 2016 Aug; 13(3):312-6. PubMed ID: 26810762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
    Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
    Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
    Miyamoto A; Morokawa N; Takahashi Y; Ogawa K; Takeyasu M; Murase K; Hanada S; Uruga H; Mochizuki S; Takaya H; Kurosaki A; Kishi K
    Intern Med; 2016; 55(6):657-61. PubMed ID: 26984086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
    Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
    Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.
    Bando M; Yamauchi H; Ogura T; Taniguchi H; Watanabe K; Azuma A; Homma S; Sugiyama Y;
    Intern Med; 2016; 55(5):443-8. PubMed ID: 26935361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pleuroparenchymal fibroelastosis (PPFE) - A case study of a rare entity.
    Boerner EB; Costabel U; Wessendorf TE; Theegarten D; Bonella F
    Rev Port Pneumol (2006); 2017; 23(6):352-355. PubMed ID: 28780989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adolescent with idiopathic pleuroparenchymal fibroelastosis. Case report.
    Atag E; Bas Ikizoglu N; Gokdemir Y; Erdem Eralp E; Kiyan G; Yilmazbayhan D; Karadag B
    Arch Argent Pediatr; 2018 Feb; 116(1):e147-e150. PubMed ID: 29333842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
    Maher TM; Lancaster LH; Jouneau S; Morrison L; Lederer DJ; Molina-Molina M; Bendstrup E; Kirchgaessler KU; Gilberg F; Axmann J; Petzinger U; Noble PW
    Ann Am Thorac Soc; 2019 Jul; 16(7):927-930. PubMed ID: 30950636
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical features of idiopathic pleuroparenchymal fibroelastosis with progressive phenotype showing a decline in forced vital capacity.
    Kono M; Tsunoda T; Ikeda S; Yagi S; Hirama R; Watanuki M; Oshima Y; Tsutsumi A; Miwa H; Miki Y; Hashimoto D; Suda T; Nakamura H
    Respir Investig; 2023 Mar; 61(2):210-219. PubMed ID: 36773509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients.
    Kusagaya H; Nakamura Y; Kono M; Kaida Y; Kuroishi S; Enomoto N; Fujisawa T; Koshimizu N; Yokomura K; Inui N; Suda T; Colby TV; Chida K
    BMC Pulm Med; 2012 Dec; 12():72. PubMed ID: 23216996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleuroparenchymal fibroelastosis associated with aluminosilicate dust: a case report.
    Huang Z; Li S; Zhu Y; Zhu H; Yi X
    Int J Clin Exp Pathol; 2015; 8(7):8676-9. PubMed ID: 26339456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.
    Ishii H; Kinoshita Y; Kushima H; Nagata N; Watanabe K
    Chron Respir Dis; 2019; 16():1479973119867945. PubMed ID: 31387379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
    Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
    Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
    Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
    Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.